The clinical trial of Conoya's new drug for the treatment of dermatitis has successfully reached the end point of the main study.

FIFA, May 30 (FAP)-- as of press release, Conoya-B (02162.HK) is up 8.83%. According to the announcement of the company, the III phase confirmatory clinical study of CM310 recombinant humanized monoclonal antibody injection in the treatment of moderate and severe atopic dermatitis (AD) (trial scheme no. CM310AD005) has been completed and preliminary statistical analysis has been completed, and the main research endpoints have been successfully reached.